Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
REGULATORY
Data Error Delayed Japan Review of Subcutaneous Rybrevant; Approval Still Expected This Year
Japan’s Ministry of Health, Labor and Welfare (MHLW) disclosed on October 29 that the approval process for Janssen Pharmaceutical’s (J&J) subcutaneous formulation of Rybrevant (amivantamab) had been temporarily put on hold due to a data error in the company’s application…
To read the full story
Related Article
- Japan Approves Label Expansions for Braftovi, Augtyro, Uplizna, and More
November 21, 2025
- Label Expansion of Braftovi, Augtyro, Lunsumio SC Up for MHLW Panel Review
October 16, 2025
- J&J’s Subcutaneous Rybrevant Faces Delay in Japan Approval Process
September 17, 2025
- Pfizer Files Anaemetro’s Pediatric Use; Coverage Already Granted
May 26, 2025
- Darzquro Filed for High-Risk Smoldering MM in Japan: J&J
February 17, 2025
- AbbVie Files Venclexta for Untreated CLL in Japan
December 23, 2024
- BMS Files Augtyro for NTRK-Positive Solid Tumors in Japan
December 16, 2024
REGULATORY
- PMDA to Adopt General-Purpose AI in FY2025, Eyes Specialized Tools for Reviews and Safety Work
December 8, 2025
- Japan Likely to Extend Generic-Name Prescribing Premium to Biologics to Spur Biosimilars
December 8, 2025
- Aspirin, CAR-T and Other Products under PMDA Safety Review
December 8, 2025
- R&D Tax Credit Draws Broad Calls for Maintenance, Expansion: LDP Meeting
December 8, 2025
- Another LDP Study Group Submits Emergency Proposal Urging Drug Pricing Overhaul
December 5, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…